DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
49	全身性エリテマトーデス	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04447053 (ClinicalTrials.gov)	September 2020	23/6/2020	Sequential Belimumab and T-cell Based Therapy in SLE	Sequential Belimumab Followed by T-cell Based Therapy in the Treatment of Systemic Lupus Erythematosus (SUBTLE) - a Preliminary Proof-of-concept Mechanistic Study	Systemic Lupus Erythematosus	Drug: Belimumab Injection [Benlysta]	National University Hospital, Singapore	GlaxoSmithKline	Not yet recruiting	21 Years	70 Years	All	80	Phase 4	Singapore

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04447053
(ClinicalTrials.gov)

September 2020

23/6/2020

Sequential Belimumab and T-cell Based Therapy in SLE

Sequential Belimumab Followed by T-cell Based Therapy in the Treatment of Systemic Lupus Erythematosus (SUBTLE) - a Preliminary Proof-of-concept Mechanistic Study

Systemic Lupus Erythematosus

Drug: Belimumab Injection [Benlysta]

National University Hospital, Singapore

GlaxoSmithKline

Not yet recruiting

21 Years

70 Years

All

Phase 4

Singapore